Matthew McQueen
Concepts (506)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 22 | 2022 | 1526 | 1.790 |
Why?
| | Polymorphism, Single Nucleotide | 40 | 2020 | 2228 | 1.650 |
Why?
| | Genetic Predisposition to Disease | 26 | 2022 | 2455 | 1.300 |
Why?
| | Genetic Linkage | 10 | 2011 | 269 | 1.250 |
Why?
| | Troponin I | 9 | 2020 | 74 | 1.080 |
Why?
| | Troponin T | 9 | 2020 | 63 | 1.010 |
Why?
| | Waist-Height Ratio | 3 | 2016 | 8 | 0.960 |
Why?
| | Risk-Taking | 4 | 2015 | 321 | 0.800 |
Why?
| | Body Mass Index | 12 | 2015 | 2446 | 0.760 |
Why?
| | Genetic Testing | 9 | 2016 | 491 | 0.680 |
Why?
| | Acute Coronary Syndrome | 6 | 2020 | 299 | 0.670 |
Why?
| | Sexual Behavior | 3 | 2013 | 489 | 0.650 |
Why?
| | Bipolar Disorder | 5 | 2011 | 281 | 0.610 |
Why?
| | Siblings | 7 | 2014 | 196 | 0.600 |
Why?
| | Alcohol Drinking | 7 | 2022 | 847 | 0.600 |
Why?
| | Quantitative Trait, Heritable | 5 | 2016 | 118 | 0.560 |
Why?
| | Genome, Human | 9 | 2014 | 425 | 0.540 |
Why?
| | Genotype | 18 | 2019 | 1866 | 0.540 |
Why?
| | Epidemiology | 1 | 2018 | 33 | 0.540 |
Why?
| | Myocardial Infarction | 10 | 2020 | 1212 | 0.530 |
Why?
| | Cardiovascular Diseases | 13 | 2024 | 2218 | 0.520 |
Why?
| | Metabolic Syndrome | 2 | 2016 | 364 | 0.510 |
Why?
| | Quantitative Trait Loci | 4 | 2015 | 388 | 0.510 |
Why?
| | Substance-Related Disorders | 8 | 2020 | 1098 | 0.500 |
Why?
| | Databases, Genetic | 5 | 2012 | 239 | 0.470 |
Why?
| | Antisocial Personality Disorder | 2 | 2015 | 123 | 0.460 |
Why?
| | Brain Concussion | 2 | 2021 | 660 | 0.460 |
Why?
| | Alzheimer Disease | 8 | 2011 | 640 | 0.450 |
Why?
| | Teaching | 1 | 2018 | 243 | 0.450 |
Why?
| | Longitudinal Studies | 15 | 2024 | 3005 | 0.450 |
Why?
| | Waist Circumference | 1 | 2015 | 142 | 0.440 |
Why?
| | Education, Medical, Undergraduate | 1 | 2018 | 206 | 0.440 |
Why?
| | Receptors, Nicotinic | 7 | 2013 | 327 | 0.440 |
Why?
| | Alcoholism | 8 | 2020 | 830 | 0.440 |
Why?
| | Athletic Injuries | 2 | 2021 | 574 | 0.430 |
Why?
| | Humans | 122 | 2024 | 145625 | 0.430 |
Why?
| | Genetic Variation | 8 | 2022 | 992 | 0.420 |
Why?
| | Tobacco Use Disorder | 6 | 2020 | 217 | 0.410 |
Why?
| | Obesity | 9 | 2016 | 3123 | 0.400 |
Why?
| | Impulsive Behavior | 1 | 2015 | 146 | 0.390 |
Why?
| | Gene-Environment Interaction | 2 | 2014 | 188 | 0.380 |
Why?
| | Blood Pressure | 8 | 2018 | 1761 | 0.380 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 2097 | 0.380 |
Why?
| | Public Health | 1 | 2018 | 573 | 0.380 |
Why?
| | Conduct Disorder | 5 | 2015 | 159 | 0.360 |
Why?
| | Aging | 6 | 2020 | 1983 | 0.360 |
Why?
| | Male | 74 | 2024 | 73014 | 0.350 |
Why?
| | Breast Feeding | 1 | 2015 | 447 | 0.350 |
Why?
| | Natriuretic Peptide, Brain | 4 | 2024 | 110 | 0.340 |
Why?
| | Female | 71 | 2024 | 79080 | 0.340 |
Why?
| | Genetic Loci | 4 | 2022 | 272 | 0.330 |
Why?
| | Phenotype | 17 | 2020 | 3186 | 0.330 |
Why?
| | Sodium, Dietary | 4 | 2018 | 43 | 0.330 |
Why?
| | Sodium | 3 | 2018 | 196 | 0.320 |
Why?
| | Carrier State | 2 | 2021 | 80 | 0.320 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2010 | 50 | 0.300 |
Why?
| | Myocardium | 3 | 2020 | 948 | 0.290 |
Why?
| | Clinical Laboratory Techniques | 3 | 2020 | 96 | 0.290 |
Why?
| | Pedigree | 3 | 2013 | 507 | 0.290 |
Why?
| | Adult | 36 | 2020 | 40821 | 0.270 |
Why?
| | Risk Factors | 26 | 2022 | 10840 | 0.270 |
Why?
| | Apolipoprotein E4 | 2 | 2007 | 47 | 0.270 |
Why?
| | Apolipoprotein E2 | 1 | 2007 | 4 | 0.270 |
Why?
| | alpha-Macroglobulins | 1 | 2007 | 24 | 0.260 |
Why?
| | Biometry | 2 | 2007 | 66 | 0.260 |
Why?
| | Body Weight | 5 | 2015 | 964 | 0.260 |
Why?
| | Adolescent | 25 | 2021 | 22451 | 0.250 |
Why?
| | Young Adult | 17 | 2021 | 14240 | 0.250 |
Why?
| | Multifactorial Inheritance | 2 | 2022 | 242 | 0.240 |
Why?
| | Emergency Service, Hospital | 8 | 2020 | 2357 | 0.240 |
Why?
| | Middle Aged | 35 | 2024 | 36359 | 0.240 |
Why?
| | Blood Glucose | 9 | 2018 | 2357 | 0.230 |
Why?
| | Family | 7 | 2011 | 680 | 0.230 |
Why?
| | Linkage Disequilibrium | 7 | 2020 | 257 | 0.230 |
Why?
| | Sodium Nitrite | 2 | 2015 | 39 | 0.220 |
Why?
| | Models, Genetic | 8 | 2016 | 537 | 0.220 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2005 | 40 | 0.220 |
Why?
| | Memory | 1 | 2007 | 298 | 0.220 |
Why?
| | Aged | 32 | 2024 | 26251 | 0.220 |
Why?
| | Biomarkers | 11 | 2024 | 4329 | 0.220 |
Why?
| | Asymptomatic Infections | 2 | 2021 | 40 | 0.210 |
Why?
| | Filgrastim | 1 | 2024 | 13 | 0.210 |
Why?
| | Diet, Sodium-Restricted | 2 | 2016 | 39 | 0.210 |
Why?
| | Feeding and Eating Disorders | 2 | 2020 | 162 | 0.200 |
Why?
| | Internationality | 2 | 2022 | 156 | 0.200 |
Why?
| | Endothelium, Vascular | 3 | 2016 | 952 | 0.200 |
Why?
| | Heart Diseases | 2 | 2017 | 341 | 0.200 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2024 | 28 | 0.200 |
Why?
| | Population Health | 1 | 2024 | 44 | 0.190 |
Why?
| | HIV Infections | 3 | 2013 | 3210 | 0.190 |
Why?
| | Health Status | 2 | 2018 | 822 | 0.190 |
Why?
| | Cooperative Behavior | 1 | 2005 | 467 | 0.180 |
Why?
| | ROC Curve | 4 | 2017 | 613 | 0.180 |
Why?
| | Cholesterol, HDL | 3 | 2016 | 201 | 0.180 |
Why?
| | Saliva | 2 | 2021 | 256 | 0.180 |
Why?
| | Viral Load | 2 | 2021 | 525 | 0.180 |
Why?
| | Prospective Studies | 10 | 2021 | 8087 | 0.180 |
Why?
| | Nerve Tissue Proteins | 4 | 2011 | 594 | 0.180 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3396 | 0.180 |
Why?
| | Case-Control Studies | 15 | 2019 | 3633 | 0.180 |
Why?
| | Tobacco Use | 1 | 2022 | 67 | 0.170 |
Why?
| | Peptide Fragments | 4 | 2024 | 693 | 0.170 |
Why?
| | Hypertension | 4 | 2016 | 1270 | 0.170 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2012 | 61 | 0.170 |
Why?
| | Lipids | 3 | 2018 | 715 | 0.170 |
Why?
| | Glomerular Filtration Rate | 4 | 2018 | 743 | 0.170 |
Why?
| | Prediabetic State | 1 | 2024 | 250 | 0.160 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 1136 | 0.160 |
Why?
| | Smoking | 5 | 2019 | 1478 | 0.160 |
Why?
| | Receptors, GABA-A | 2 | 2014 | 138 | 0.160 |
Why?
| | Gastrointestinal Microbiome | 2 | 2020 | 767 | 0.160 |
Why?
| | Diseases in Twins | 2 | 2012 | 114 | 0.160 |
Why?
| | Mental Disorders | 3 | 2019 | 1133 | 0.160 |
Why?
| | Alleles | 5 | 2018 | 900 | 0.160 |
Why?
| | Gene Frequency | 10 | 2011 | 495 | 0.150 |
Why?
| | Brachial Artery | 3 | 2016 | 206 | 0.150 |
Why?
| | Risk | 4 | 2020 | 917 | 0.150 |
Why?
| | Immunoassay | 1 | 2020 | 108 | 0.150 |
Why?
| | Reference Values | 4 | 2016 | 787 | 0.150 |
Why?
| | Polyethylene Glycols | 1 | 2024 | 649 | 0.150 |
Why?
| | Multigene Family | 2 | 2011 | 209 | 0.150 |
Why?
| | Genetic Markers | 4 | 2014 | 337 | 0.140 |
Why?
| | Data Interpretation, Statistical | 3 | 2011 | 365 | 0.140 |
Why?
| | Risk Assessment | 8 | 2020 | 3678 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2020 | 108 | 0.140 |
Why?
| | Minisatellite Repeats | 1 | 2019 | 36 | 0.140 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 271 | 0.140 |
Why?
| | Global Health | 4 | 2016 | 402 | 0.140 |
Why?
| | Behavior | 1 | 2019 | 90 | 0.140 |
Why?
| | Adolescent Behavior | 2 | 2013 | 486 | 0.140 |
Why?
| | Schizophrenia | 3 | 2020 | 476 | 0.140 |
Why?
| | Vascular Stiffness | 3 | 2018 | 488 | 0.130 |
Why?
| | Healthy Aging | 1 | 2018 | 44 | 0.130 |
Why?
| | Feces | 2 | 2020 | 494 | 0.130 |
Why?
| | Pandemics | 2 | 2024 | 1700 | 0.130 |
Why?
| | Genetic Association Studies | 4 | 2014 | 376 | 0.130 |
Why?
| | Sodium Pertechnetate Tc 99m | 2 | 1997 | 4 | 0.130 |
Why?
| | Marijuana Abuse | 1 | 2020 | 215 | 0.130 |
Why?
| | Biological Specimen Banks | 1 | 2019 | 137 | 0.130 |
Why?
| | Likelihood Functions | 2 | 2015 | 138 | 0.130 |
Why?
| | NAD | 1 | 2018 | 80 | 0.130 |
Why?
| | Students | 2 | 2021 | 647 | 0.130 |
Why?
| | Body Height | 2 | 2015 | 202 | 0.130 |
Why?
| | Caloric Restriction | 2 | 2018 | 133 | 0.130 |
Why?
| | Athletes | 1 | 2021 | 430 | 0.130 |
Why?
| | Niacinamide | 1 | 2018 | 103 | 0.130 |
Why?
| | Mouth | 1 | 2017 | 84 | 0.130 |
Why?
| | Cholesterol, LDL | 2 | 2016 | 363 | 0.120 |
Why?
| | Exercise | 3 | 2018 | 2206 | 0.120 |
Why?
| | Apolipoprotein B-100 | 1 | 2016 | 13 | 0.120 |
Why?
| | Hair | 2 | 2015 | 81 | 0.120 |
Why?
| | Psychological Trauma | 1 | 2017 | 58 | 0.120 |
Why?
| | Burns | 1 | 2021 | 365 | 0.120 |
Why?
| | Apolipoprotein A-I | 1 | 2016 | 39 | 0.120 |
Why?
| | Regional Blood Flow | 2 | 2016 | 507 | 0.120 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2016 | 44 | 0.120 |
Why?
| | Chromosome Mapping | 5 | 2015 | 505 | 0.120 |
Why?
| | Trehalose | 1 | 2016 | 35 | 0.120 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2016 | 37 | 0.120 |
Why?
| | Europe | 5 | 2022 | 420 | 0.110 |
Why?
| | Cognitive Dysfunction | 1 | 2022 | 479 | 0.110 |
Why?
| | Gene Regulatory Networks | 2 | 2018 | 319 | 0.110 |
Why?
| | Cross-Sectional Studies | 6 | 2013 | 5875 | 0.110 |
Why?
| | Algorithms | 3 | 2020 | 1843 | 0.110 |
Why?
| | Cohort Studies | 9 | 2020 | 6045 | 0.110 |
Why?
| | Sexual Partners | 2 | 2013 | 195 | 0.110 |
Why?
| | Educational Status | 2 | 2014 | 466 | 0.110 |
Why?
| | Aged, 80 and over | 7 | 2020 | 8351 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 26 | 0.110 |
Why?
| | Amino Acids | 1 | 2018 | 513 | 0.100 |
Why?
| | Carotid Arteries | 1 | 2015 | 206 | 0.100 |
Why?
| | Quality Control | 1 | 2014 | 162 | 0.100 |
Why?
| | United States | 5 | 2016 | 16041 | 0.100 |
Why?
| | Health Surveys | 1 | 2016 | 511 | 0.100 |
Why?
| | Odds Ratio | 6 | 2016 | 1070 | 0.100 |
Why?
| | Proteome | 1 | 2018 | 520 | 0.100 |
Why?
| | Malawi | 1 | 2013 | 58 | 0.100 |
Why?
| | Hindlimb | 1 | 2014 | 128 | 0.100 |
Why?
| | Polymorphism, Genetic | 3 | 2012 | 611 | 0.100 |
Why?
| | Albuminuria | 1 | 2014 | 190 | 0.100 |
Why?
| | Income | 1 | 2014 | 205 | 0.100 |
Why?
| | Locomotion | 1 | 2014 | 102 | 0.100 |
Why?
| | Nervous System Physiological Phenomena | 1 | 2013 | 22 | 0.090 |
Why?
| | Physical Exertion | 1 | 2014 | 204 | 0.090 |
Why?
| | Colorado | 4 | 2021 | 4588 | 0.090 |
Why?
| | Metabolic Networks and Pathways | 1 | 2014 | 175 | 0.090 |
Why?
| | Metformin | 1 | 2016 | 328 | 0.090 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 128 | 0.090 |
Why?
| | Transplantation | 1 | 2013 | 31 | 0.090 |
Why?
| | Double-Blind Method | 5 | 2018 | 2064 | 0.090 |
Why?
| | Metabolomics | 1 | 2018 | 737 | 0.090 |
Why?
| | Telomere | 1 | 2016 | 300 | 0.090 |
Why?
| | Aorta | 1 | 2015 | 440 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2024 | 2623 | 0.090 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 89 | 0.090 |
Why?
| | Receptors, Oxytocin | 1 | 2012 | 20 | 0.090 |
Why?
| | Myocardial Ischemia | 1 | 2014 | 286 | 0.090 |
Why?
| | Lovastatin | 1 | 1992 | 37 | 0.090 |
Why?
| | Pravastatin | 1 | 1992 | 45 | 0.090 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1411 | 0.090 |
Why?
| | Canada | 5 | 2007 | 430 | 0.090 |
Why?
| | Hyperlipoproteinemia Type II | 1 | 1992 | 32 | 0.090 |
Why?
| | Genetic Heterogeneity | 3 | 2008 | 66 | 0.090 |
Why?
| | Age Factors | 6 | 2020 | 3321 | 0.090 |
Why?
| | Substance Abuse, Intravenous | 1 | 2013 | 131 | 0.090 |
Why?
| | Puberty | 1 | 2013 | 141 | 0.090 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 608 | 0.090 |
Why?
| | Haplotypes | 6 | 2010 | 505 | 0.090 |
Why?
| | Sensitivity and Specificity | 3 | 2021 | 1992 | 0.090 |
Why?
| | Prevalence | 6 | 2017 | 2852 | 0.080 |
Why?
| | Physical Fitness | 1 | 2013 | 207 | 0.080 |
Why?
| | Ramipril | 2 | 2008 | 6 | 0.080 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2011 | 8 | 0.080 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2011 | 36 | 0.080 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2011 | 54 | 0.080 |
Why?
| | Interleukins | 1 | 2013 | 247 | 0.080 |
Why?
| | Potassium | 1 | 2011 | 151 | 0.080 |
Why?
| | Receptors, Immunologic | 2 | 2013 | 210 | 0.080 |
Why?
| | Software | 2 | 2014 | 673 | 0.080 |
Why?
| | Receptors, Dopamine D4 | 1 | 2011 | 27 | 0.080 |
Why?
| | Motor Activity | 1 | 2015 | 701 | 0.080 |
Why?
| | Postural Balance | 1 | 2014 | 241 | 0.080 |
Why?
| | Glucose Metabolism Disorders | 1 | 2010 | 9 | 0.080 |
Why?
| | Child Behavior Disorders | 1 | 2011 | 117 | 0.080 |
Why?
| | Behavior, Animal | 1 | 2014 | 530 | 0.080 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2011 | 59 | 0.080 |
Why?
| | Diabetes Mellitus | 3 | 2011 | 1101 | 0.080 |
Why?
| | Follow-Up Studies | 6 | 2024 | 5397 | 0.080 |
Why?
| | Catechol O-Methyltransferase | 1 | 2010 | 20 | 0.080 |
Why?
| | Hepatitis C | 1 | 2013 | 250 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 724 | 0.080 |
Why?
| | Diet, Reducing | 1 | 2010 | 90 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 228 | 0.080 |
Why?
| | Tissue Donors | 1 | 2013 | 398 | 0.070 |
Why?
| | Life Expectancy | 1 | 2010 | 72 | 0.070 |
Why?
| | Twins, Dizygotic | 1 | 2010 | 108 | 0.070 |
Why?
| | Environment | 2 | 2010 | 295 | 0.070 |
Why?
| | Psychology, Adolescent | 1 | 2009 | 58 | 0.070 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 132 | 0.070 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2017 | 889 | 0.070 |
Why?
| | Quality of Life | 1 | 2021 | 3187 | 0.070 |
Why?
| | Isotretinoin | 1 | 2009 | 27 | 0.070 |
Why?
| | Hyperhomocysteinemia | 1 | 2009 | 26 | 0.070 |
Why?
| | Ontario | 2 | 2020 | 91 | 0.070 |
Why?
| | Insulin Glargine | 2 | 2022 | 88 | 0.070 |
Why?
| | Acne Vulgaris | 1 | 2009 | 25 | 0.070 |
Why?
| | Hypertriglyceridemia | 1 | 2009 | 45 | 0.070 |
Why?
| | Energy Metabolism | 1 | 2015 | 930 | 0.070 |
Why?
| | Genes, Neoplasm | 1 | 2008 | 26 | 0.070 |
Why?
| | Longevity | 1 | 2010 | 179 | 0.070 |
Why?
| | Benzoates | 1 | 2008 | 48 | 0.070 |
Why?
| | Dermatologic Agents | 1 | 2009 | 69 | 0.070 |
Why?
| | Homocysteine | 1 | 2009 | 152 | 0.070 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 39 | 0.070 |
Why?
| | Raphe Nuclei | 2 | 1999 | 112 | 0.070 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6050 | 0.070 |
Why?
| | Myosin Type V | 1 | 2008 | 9 | 0.070 |
Why?
| | Proteinuria | 1 | 2008 | 103 | 0.070 |
Why?
| | Universities | 2 | 2021 | 450 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 183 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2013 | 2910 | 0.060 |
Why?
| | Benzimidazoles | 1 | 2008 | 189 | 0.060 |
Why?
| | Cognition | 1 | 2015 | 1286 | 0.060 |
Why?
| | Myosin Heavy Chains | 1 | 2008 | 177 | 0.060 |
Why?
| | Death | 2 | 2018 | 129 | 0.060 |
Why?
| | Triglycerides | 2 | 2003 | 527 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 1 | 2006 | 54 | 0.060 |
Why?
| | Prognosis | 4 | 2021 | 4331 | 0.060 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 421 | 0.060 |
Why?
| | Task Performance and Analysis | 1 | 2007 | 203 | 0.060 |
Why?
| | Antigens, Neoplasm | 1 | 2008 | 271 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2013 | 699 | 0.060 |
Why?
| | Pharmacogenetics | 1 | 2007 | 176 | 0.060 |
Why?
| | China | 3 | 2007 | 278 | 0.060 |
Why?
| | Sex Factors | 4 | 2017 | 2101 | 0.060 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2005 | 26 | 0.060 |
Why?
| | Heart Failure | 2 | 2011 | 2323 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2005 | 119 | 0.060 |
Why?
| | Parkinson Disease | 1 | 2012 | 614 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2008 | 495 | 0.050 |
Why?
| | Biological Availability | 2 | 2012 | 146 | 0.050 |
Why?
| | Hematologic Agents | 1 | 2024 | 3 | 0.050 |
Why?
| | Febrile Neutropenia | 1 | 2024 | 6 | 0.050 |
Why?
| | ErbB Receptors | 1 | 2008 | 636 | 0.050 |
Why?
| | Chemical Phenomena | 1 | 2024 | 75 | 0.050 |
Why?
| | Anxiety Disorders | 2 | 2021 | 351 | 0.050 |
Why?
| | Ankle Brachial Index | 1 | 2024 | 41 | 0.050 |
Why?
| | Comorbidity | 4 | 2013 | 1652 | 0.050 |
Why?
| | Stroke | 2 | 2011 | 1283 | 0.050 |
Why?
| | Metabolome | 2 | 2018 | 390 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 207 | 0.050 |
Why?
| | Cognition Disorders | 1 | 2007 | 547 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2006 | 1293 | 0.050 |
Why?
| | Chlamydophila Infections | 1 | 2003 | 5 | 0.050 |
Why?
| | Telephone | 1 | 2024 | 175 | 0.050 |
Why?
| | Helicobacter Infections | 1 | 2003 | 30 | 0.050 |
Why?
| | Hepatitis A | 1 | 2003 | 25 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2003 | 82 | 0.050 |
Why?
| | Muscle, Skeletal | 1 | 2013 | 1795 | 0.050 |
Why?
| | Sample Size | 1 | 2022 | 123 | 0.050 |
Why?
| | Time Factors | 3 | 2020 | 7079 | 0.040 |
Why?
| | Child | 8 | 2021 | 22638 | 0.040 |
Why?
| | Mental Status and Dementia Tests | 1 | 2022 | 28 | 0.040 |
Why?
| | Evaluation Studies as Topic | 2 | 2020 | 160 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2024 | 427 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 627 | 0.040 |
Why?
| | Incidence | 2 | 2019 | 2910 | 0.040 |
Why?
| | Logistic Models | 2 | 2016 | 2112 | 0.040 |
Why?
| | Dietary Supplements | 2 | 2015 | 586 | 0.040 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2021 | 39 | 0.040 |
Why?
| | Kidney Diseases | 1 | 2005 | 427 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2014 | 2962 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2003 | 203 | 0.040 |
Why?
| | Pilot Projects | 2 | 2017 | 1878 | 0.040 |
Why?
| | Virion | 1 | 2021 | 112 | 0.040 |
Why?
| | Kidney | 1 | 2008 | 1491 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2018 | 0.040 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 221 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 104 | 0.040 |
Why?
| | Luminescence | 1 | 2020 | 37 | 0.040 |
Why?
| | Serotonin | 2 | 1999 | 297 | 0.040 |
Why?
| | Patient Selection | 2 | 2008 | 720 | 0.040 |
Why?
| | Electrochemical Techniques | 1 | 2020 | 55 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1030 | 0.040 |
Why?
| | Specimen Handling | 1 | 2021 | 178 | 0.040 |
Why?
| | Opioid Peptides | 1 | 1999 | 9 | 0.040 |
Why?
| | Genetics, Behavioral | 1 | 2019 | 17 | 0.040 |
Why?
| | Escape Reaction | 1 | 1999 | 55 | 0.040 |
Why?
| | Asia, Southeastern | 1 | 1998 | 13 | 0.040 |
Why?
| | Computer Simulation | 3 | 2010 | 1014 | 0.040 |
Why?
| | Apolipoproteins | 2 | 2004 | 38 | 0.040 |
Why?
| | Hyperglycemia | 1 | 2003 | 381 | 0.040 |
Why?
| | Helplessness, Learned | 1 | 1999 | 67 | 0.040 |
Why?
| | Potassium, Dietary | 1 | 2018 | 12 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2005 | 1467 | 0.030 |
Why?
| | Bayes Theorem | 1 | 2020 | 424 | 0.030 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 31 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1997 | 429 | 0.030 |
Why?
| | Methionine | 1 | 2018 | 160 | 0.030 |
Why?
| | United Kingdom | 1 | 2019 | 376 | 0.030 |
Why?
| | Oxidative Stress | 2 | 2016 | 1367 | 0.030 |
Why?
| | Limit of Detection | 1 | 2017 | 92 | 0.030 |
Why?
| | Chromosomes, Human | 1 | 2017 | 45 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 2017 | 20 | 0.030 |
Why?
| | Transcription Factors | 1 | 2005 | 1728 | 0.030 |
Why?
| | Absorption | 1 | 1997 | 60 | 0.030 |
Why?
| | Troponin | 1 | 2017 | 50 | 0.030 |
Why?
| | RNA, Viral | 1 | 2021 | 691 | 0.030 |
Why?
| | Anxiety | 2 | 2021 | 1118 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 1997 | 170 | 0.030 |
Why?
| | Hospitalization | 2 | 2021 | 2468 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2017 | 182 | 0.030 |
Why?
| | Models, Biological | 2 | 2010 | 1758 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2017 | 319 | 0.030 |
Why?
| | Methemoglobin | 1 | 2015 | 24 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 1066 | 0.030 |
Why?
| | Stress, Physiological | 1 | 1999 | 449 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 375 | 0.030 |
Why?
| | Forearm | 1 | 2016 | 141 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2016 | 120 | 0.030 |
Why?
| | Acetylcholine | 1 | 2016 | 208 | 0.030 |
Why?
| | Fear | 1 | 1999 | 371 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 507 | 0.030 |
Why?
| | Mice, Congenic | 1 | 2015 | 23 | 0.030 |
Why?
| | Fatty Acids | 1 | 2018 | 460 | 0.030 |
Why?
| | Elasticity | 1 | 2015 | 187 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2008 | 751 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 771 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2008 | 2674 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 455 | 0.030 |
Why?
| | Pulse Wave Analysis | 1 | 2015 | 268 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 533 | 0.030 |
Why?
| | Brain Chemistry | 2 | 2009 | 121 | 0.030 |
Why?
| | Sibling Relations | 1 | 2014 | 10 | 0.030 |
Why?
| | Regression Analysis | 1 | 1997 | 994 | 0.030 |
Why?
| | Urban Health | 1 | 2014 | 95 | 0.030 |
Why?
| | Rural Health | 1 | 2014 | 86 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1754 | 0.030 |
Why?
| | Acute Disease | 1 | 2017 | 1033 | 0.030 |
Why?
| | Inheritance Patterns | 1 | 2014 | 47 | 0.030 |
Why?
| | Mobility Limitation | 1 | 2014 | 66 | 0.020 |
Why?
| | Unsafe Sex | 1 | 2013 | 62 | 0.020 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 7 | 0.020 |
Why?
| | Age Distribution | 1 | 2014 | 395 | 0.020 |
Why?
| | Condoms | 1 | 2013 | 99 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2218 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1300 | 0.020 |
Why?
| | Vasodilation | 1 | 2015 | 519 | 0.020 |
Why?
| | Research Design | 1 | 1998 | 1139 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 2078 | 0.020 |
Why?
| | Microcirculation | 1 | 2012 | 142 | 0.020 |
Why?
| | Genomics | 1 | 2017 | 851 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1992 | 99 | 0.020 |
Why?
| | Interferons | 1 | 2013 | 186 | 0.020 |
Why?
| | Urinalysis | 1 | 2011 | 82 | 0.020 |
Why?
| | Mice | 3 | 2015 | 18266 | 0.020 |
Why?
| | Vascular Resistance | 1 | 2012 | 365 | 0.020 |
Why?
| | Muscle Strength | 1 | 2014 | 332 | 0.020 |
Why?
| | Infusions, Parenteral | 1 | 1991 | 47 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2015 | 883 | 0.020 |
Why?
| | Phobic Disorders | 1 | 2011 | 36 | 0.020 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 2011 | 46 | 0.020 |
Why?
| | Urban Population | 1 | 2014 | 496 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2012 | 612 | 0.020 |
Why?
| | Sodium Chloride | 1 | 1991 | 138 | 0.020 |
Why?
| | Rodentia | 1 | 2010 | 62 | 0.020 |
Why?
| | Neurons | 1 | 1999 | 1663 | 0.020 |
Why?
| | Animals | 5 | 2015 | 38030 | 0.020 |
Why?
| | Recovery of Function | 1 | 2014 | 721 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2010 | 384 | 0.020 |
Why?
| | Nuclear Family | 1 | 2009 | 50 | 0.020 |
Why?
| | Fluid Therapy | 1 | 1991 | 152 | 0.020 |
Why?
| | Coronary Disease | 1 | 1992 | 380 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1125 | 0.020 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2009 | 7 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1073 | 0.020 |
Why?
| | Vitamin B 6 | 1 | 2009 | 11 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2010 | 192 | 0.020 |
Why?
| | Dizziness | 1 | 2010 | 93 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2009 | 67 | 0.020 |
Why?
| | Vitamin B Complex | 1 | 2009 | 39 | 0.020 |
Why?
| | Fertility | 1 | 2010 | 173 | 0.020 |
Why?
| | Inflammation | 1 | 2020 | 2915 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 511 | 0.020 |
Why?
| | Tetraspanins | 1 | 2008 | 19 | 0.020 |
Why?
| | Vitamin B 12 | 1 | 2009 | 139 | 0.020 |
Why?
| | Medical History Taking | 1 | 2008 | 116 | 0.020 |
Why?
| | Pyrroles | 1 | 2009 | 221 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2008 | 67 | 0.020 |
Why?
| | Bias | 1 | 2008 | 196 | 0.020 |
Why?
| | Sri Lanka | 1 | 2007 | 8 | 0.020 |
Why?
| | Folic Acid | 1 | 2009 | 197 | 0.020 |
Why?
| | Internet | 1 | 2012 | 656 | 0.020 |
Why?
| | Disability Evaluation | 1 | 2009 | 297 | 0.020 |
Why?
| | Anticholesteremic Agents | 1 | 2009 | 156 | 0.020 |
Why?
| | Energy Intake | 1 | 2010 | 506 | 0.020 |
Why?
| | Bangladesh | 1 | 2007 | 64 | 0.020 |
Why?
| | Pakistan | 1 | 2007 | 83 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 375 | 0.020 |
Why?
| | India | 1 | 2007 | 213 | 0.020 |
Why?
| | Creatinine | 1 | 2008 | 511 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 959 | 0.010 |
Why?
| | Genes, Recessive | 1 | 2006 | 77 | 0.010 |
Why?
| | Age of Onset | 1 | 2007 | 557 | 0.010 |
Why?
| | Asthma | 2 | 2010 | 1800 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2007 | 360 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1034 | 0.010 |
Why?
| | Data Collection | 1 | 2008 | 647 | 0.010 |
Why?
| | Linear Models | 1 | 2007 | 847 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 1236 | 0.010 |
Why?
| | Dyslipidemias | 1 | 2007 | 184 | 0.010 |
Why?
| | Placebos | 1 | 2005 | 190 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2005 | 152 | 0.010 |
Why?
| | Vitamin E | 1 | 2005 | 123 | 0.010 |
Why?
| | Heterozygote | 1 | 2005 | 310 | 0.010 |
Why?
| | Body Constitution | 1 | 2004 | 51 | 0.010 |
Why?
| | Smoking Cessation | 1 | 2008 | 440 | 0.010 |
Why?
| | Cross-Cultural Comparison | 1 | 2004 | 75 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1318 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1859 | 0.010 |
Why?
| | Fasting | 1 | 2005 | 280 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 2005 | 265 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 2 | 1999 | 2533 | 0.010 |
Why?
| | RNA | 1 | 2010 | 925 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2005 | 310 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4565 | 0.010 |
Why?
| | Hepatitis A virus | 1 | 2003 | 1 | 0.010 |
Why?
| | Chlamydophila pneumoniae | 1 | 2003 | 12 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 456 | 0.010 |
Why?
| | Asia | 1 | 2003 | 69 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 6021 | 0.010 |
Why?
| | Helicobacter pylori | 1 | 2003 | 44 | 0.010 |
Why?
| | Diabetes Complications | 1 | 2004 | 219 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 2003 | 169 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 17291 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 2003 | 147 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 613 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 365 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2003 | 169 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1051 | 0.010 |
Why?
| | Glucose Intolerance | 1 | 2003 | 142 | 0.010 |
Why?
| | DNA | 1 | 2008 | 1418 | 0.010 |
Why?
| | Parents | 1 | 2010 | 1393 | 0.010 |
Why?
| | Rats | 2 | 1999 | 5574 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2004 | 1323 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2006 | 1130 | 0.010 |
Why?
| | Survival Analysis | 1 | 2003 | 1372 | 0.010 |
Why?
| | Reinforcement Schedule | 1 | 1999 | 25 | 0.010 |
Why?
| | Microinjections | 1 | 1999 | 92 | 0.010 |
Why?
| | Electroshock | 1 | 1999 | 146 | 0.010 |
Why?
| | Periaqueductal Gray | 1 | 1999 | 37 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2003 | 683 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2007 | 1247 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 1999 | 193 | 0.010 |
Why?
| | Catheterization | 1 | 1999 | 178 | 0.010 |
Why?
| | Morphine | 1 | 1999 | 169 | 0.010 |
Why?
| | Naltrexone | 1 | 1999 | 114 | 0.010 |
Why?
| | Narcotic Antagonists | 1 | 1999 | 209 | 0.010 |
Why?
| | Diet | 1 | 2004 | 1271 | 0.010 |
Why?
| | Insulin | 1 | 2007 | 2524 | 0.010 |
Why?
| | Infant | 1 | 2008 | 10093 | 0.010 |
Why?
| | Child, Preschool | 1 | 2008 | 11888 | 0.010 |
Why?
| | Hyaluronoglucosaminidase | 1 | 1991 | 7 | 0.010 |
Why?
| | Tritium | 1 | 1991 | 64 | 0.010 |
Why?
| | Analgesics, Opioid | 1 | 1999 | 1158 | 0.000 |
Why?
| | Depression | 1 | 1999 | 1566 | 0.000 |
Why?
|
|
McQueen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|